ウイルスベクター製造市場：タイプ、疾患、用途別-2025-2030年の世界予測

ウイルスベクター製造市場は、2023年に10億5,000万米ドルと評価され、2024年には12億5,000万米ドルに達すると予測され、CAGR 19.11％で成長し、2030年には35億9,000万米ドルに達すると予測されています。

ウイルスベクター製造は、遺伝子治療、ワクチン生産、その他の新規医療用途の分野で重要な役割を果たしています。これらのベクターは、遺伝物質を細胞内に輸送するデリバリー・ビークルとして機能し、遺伝的障害を修正したり、望ましい細胞反応を誘発したりするために重要なプロセスです。ウイルスベクターの必要性は、幅広い種類の細胞を効果的に形質導入するその能力からきており、高度な治療法やワクチンの開発に不可欠なものとなっています。その応用範囲は、希少な遺伝性疾患への対応から広範なワクチン生産にまで及び、COVID-19ワクチン開発におけるウイルスベクター・プラットフォームの成功が最も顕著に示しています。最終用途には、製薬会社、バイオテクノロジー企業、研究機関、製造受託機関などが含まれ、これらの企業はこれらの技術の活用に深く投資しています。ウイルスベクター製造の市場成長の原動力は、遺伝子治療の承認が増加し、遺伝性疾患や慢性疾患の罹患率が上昇し、革新的な治療ソリューションに対する需要が高まっていることです。さらに、研究協力の拡大やバイオテクノロジー分野への投資の増加が研究開発に拍車をかけ、有利な機会をもたらしています。しかし、市場は、高い製造コスト、複雑な規制状況、拡張性の問題など、いくつかの課題に直面しており、潜在能力の完全な実現を妨げています。技術革新は、ベクターの生産性向上、コスト削減、送達効率の改善に引き続き焦点が当てられており、研究は新規ベクタータイプと拡張可能な生産技術の開発に傾注しています。市場の性質はアグレッシブで急速に変化しており、競争優位性を維持するためには利害関係者に俊敏性と先見性が求められます。ビジネス成長の機会は、生産メカニズムの合理化と、これらの画期的な治療法への消費者のアクセスを大幅に拡大しうる価格問題への対処にあります。パートナーシップを重視し、最先端の研究に投資することで、市場参入と拡大を促進することもできます。組織は、コスト関連の制約に取り組み、市場での地位を強化するために、プロセス効率の最適化と生産能力の拡大に注力すべきです。

市場力学：急速に進化するウイルスベクター製造市場の主要市場インサイトを公開

ウイルスベクター製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん、代謝性疾患、心臓疾患などの疾病の有病率の増加
  • 遺伝子治療開発の成長
  • ウイルスベクターによる遺伝子治療の臨床試験登録の増加
• 市場抑制要因
  • ウイルスベクターの保存期間の制限
• 市場機会
  • 収量最適化への高い関心
  • ウイルスベクター製造における技術革新
• 市場の課題
  • ウイルスベクター製造に対する厳しい規制ガイダンス

ポーターの5つの力：ウイルスベクター製造市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、ウイルスベクター製造市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ウイルスベクター製造市場における外部からの影響の把握

外部マクロ環境要因は、ウイルスベクター製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ウイルスベクター製造市場における競合情勢の把握

ウイルスベクター製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスウイルスベクター製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ウイルスベクター製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ウイルスベクター製造市場における成功への道筋を描く

ウイルスベクター製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん、代謝性疾患、心臓欠陥などの疾患の罹患率の増加
    • 遺伝子治療の開発の成長
    • ウイルスベクターを介した遺伝子治療の臨床試験の登録増加
  • 抑制要因
    • ウイルスベクターの保存期間が限られている
  • 機会
    • 収益の最適化に重点を置く
    • ウイルスベクター製造における技術革新
  • 課題
    • ウイルスベクター製造に関する厳格な規制ガイダンス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ウイルスベクター製造市場：タイプ別

• アデノ随伴ウイルスベクター
• アデノウイルスベクター
• レンチウイルスベクター
• レトロウイルスベクター

第7章 ウイルスベクター製造市場：疾患別

• がん
• 遺伝性疾患
• 感染症

第8章 ウイルスベクター製造市場：用途別

• 遺伝子治療
• ワクチン学

第9章 南北アメリカのウイルスベクター製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のウイルスベクター製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのウイルスベクター製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ABL Inc.
• Beckman Coulter, Inc.
• Biovian Oy
• Charles River Laboratories International, Inc.
• Cytiva
• Finvector
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Genezen Laboratories, Inc.
• Lonza Group Ltd.
• Merck KGaA
• Novartis AG
• Sanofi SA
• Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• uniQure N.V.

LIST OF FIGURES

• FIGURE 1. VIRAL VECTOR MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. VIRAL VECTOR MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VIRAL VECTOR MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ITALY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. POLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. QATAR VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Viral Vector Manufacturing Market was valued at USD 1.05 billion in 2023, expected to reach USD 1.25 billion in 2024, and is projected to grow at a CAGR of 19.11%, to USD 3.59 billion by 2030.

Viral vector manufacturing plays a crucial role in the field of gene therapy, vaccine production, and other novel medical applications. These vectors serve as delivery vehicles to transport genetic material into cells, a process critical for correcting genetic disorders or instigating a desired cellular response. The necessity of viral vectors stems from their ability to effectively transduce a broad spectrum of cell types, making them indispensable in the development of advanced therapies and vaccines. Their application spans from addressing rare genetic disorders to broad-based vaccine production, demonstrated most prominently by the success of viral vector platforms in COVID-19 vaccine development. The end-use scope includes pharmaceutical and biotechnology companies, research institutions, and contract manufacturing organizations that are deeply invested in harnessing these technologies. Market growth for viral vector manufacturing is driven by increasing approvals of gene therapies and rising incidences of genetic and chronic diseases, which heighten demand for innovative therapeutic solutions. Additionally, expanding research collaborations and escalating investments in the biotech sector fuel development, presenting lucrative opportunities. However, the market faces several challenges, such as high manufacturing costs, complex regulatory landscapes, and scalability issues, hindering full potential realization. Innovation continues to focus on enhancing vector productivity, reducing costs, and improving delivery efficiency, with research gravitating towards developing novel vector types and scalable production technologies. The market's nature is aggressive and rapidly changing, demanding agility and foresight from stakeholders to maintain competitive advantage. Opportunities for business growth lie in streamlining production mechanisms and addressing affordability issues, which could significantly expand consumer access to these groundbreaking therapies. Emphasizing partnerships and investment in cutting-edge research can also facilitate market entry and expansion. Organizations should focus on optimizing process efficiencies and scaling up production capabilities to tackle cost-related constraints and fortify market position.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vector Manufacturing Market

The Viral Vector Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in prevalence of disease such as cancer, metabolic diseases, heart defects
  • Growth in development of gene therapy
  • Rise in registration of clinical trials for viral vector-mediated gene therapy
• Market Restraints
  • Limited shelf-life of viral vector
• Market Opportunities
  • High focus on yield optimization
  • Technology innovation in viral vector manufacturing
• Market Challenges
  • Strict regulatory guidance for viral vector manufacturing

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vector Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vector Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vector Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vector Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vector Manufacturing Market

A detailed market share analysis in the Viral Vector Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vector Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vector Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Vector Manufacturing Market

A strategic analysis of the Viral Vector Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector Manufacturing Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Beckman Coulter, Inc., Biovian Oy, Charles River Laboratories International, Inc., Cytiva, Finvector, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Genezen Laboratories, Inc., Lonza Group Ltd., Merck KGaA, Novartis AG, Sanofi SA, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and uniQure N.V..

Market Segmentation & Coverage

This research report categorizes the Viral Vector Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Adeno-associated Viral Vectors, Adenoviral Vectors, Lentiviral Vectors, and Retroviral Vectors.
• Based on Disease, market is studied across Cancer, Genetic Disorders, and Infectious Diseases.
• Based on Application, market is studied across Gene Therapy and Vaccinology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in prevalence of disease such as cancer, metabolic diseases, heart defects
    • 5.1.1.2. Growth in development of gene therapy
    • 5.1.1.3. Rise in registration of clinical trials for viral vector-mediated gene therapy
  • 5.1.2. Restraints
    • 5.1.2.1. Limited shelf-life of viral vector
  • 5.1.3. Opportunities
    • 5.1.3.1. High focus on yield optimization
    • 5.1.3.2. Technology innovation in viral vector manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory guidance for viral vector manufacturing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Viral Vector Manufacturing Market, by Type

• 6.1. Introduction
• 6.2. Adeno-associated Viral Vectors
• 6.3. Adenoviral Vectors
• 6.4. Lentiviral Vectors
• 6.5. Retroviral Vectors

7. Viral Vector Manufacturing Market, by Disease

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Genetic Disorders
• 7.4. Infectious Diseases

8. Viral Vector Manufacturing Market, by Application

• 8.1. Introduction
• 8.2. Gene Therapy
• 8.3. Vaccinology

9. Americas Viral Vector Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Viral Vector Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Viral Vector Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ABL Inc.
• 2. Beckman Coulter, Inc.
• 3. Biovian Oy
• 4. Charles River Laboratories International, Inc.
• 5. Cytiva
• 6. Finvector
• 7. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 8. Genezen Laboratories, Inc.
• 9. Lonza Group Ltd.
• 10. Merck KGaA
• 11. Novartis AG
• 12. Sanofi SA
• 13. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
• 14. Thermo Fisher Scientific Inc.
• 15. uniQure N.V.